Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
NL202100762
Phase 1 other active
Quick answer
Takeda Brentuximab; Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma for Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma is a Phase 1 program (other) at Disc Medicine with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Disc Medicine
- Indication
- Patients with stage II-IV high risk diffuse large B-cell lymphoma, defined as international prognostic index > 2, Lymphoma
- Phase
- Phase 1
- Modality
- other
- Status
- active